U.S. Pharma Stock News

NYSE:STNG
NYSE:STNGOil and Gas

Scorpio Tankers Refines Fleet Mix With Vessel Sales And Long Charters

Scorpio Tankers (NYSE:STNG) has agreed to sell three product tankers built in 2015. The company has also entered into multi year time charter agreements for two LR2 product tankers. These moves affect Scorpio Tankers' fleet mix, contracted revenue visibility, and use of capital. Scorpio Tankers, trading at $75.29, has seen its share price gain 51.5% year to date and 104.1% over the past year, with a 356.9% return over five years. In that context, changes to the fleet and contract profile...
NYSE:FCF
NYSE:FCFBanks

Is There Now An Opportunity In First Commonwealth Financial (FCF) After Recent Share Price Pullback

If you are wondering whether First Commonwealth Financial's current share price offers good value, this article will walk through what the numbers are saying and where that might leave you as an investor. The stock last closed at US$16.98, with returns of 14.1% over the past year and 1.3% year to date, alongside short term moves of a 4.7% decline over 7 days and a 9.8% decline over 30 days that may be reshaping risk and return expectations. Recent coverage has focused on First Commonwealth...
NasdaqGS:AAL
NasdaqGS:AALAirlines

Is American Airlines Group (AAL) Now Attractive After Recent Share Price Weakness?

Wondering whether American Airlines Group shares are starting to look interesting at current levels, or if the price is telling you to be cautious? This article focuses on what the numbers say about value. The stock last closed at US$11.11, with returns of 1.6% over 1 year but declines of 10.8% over 7 days, 25.9% over 30 days, and 28.2% year to date. These moves can change how investors view both risk and potential reward. Recent headlines have continued to focus on the big picture for US...
NYSE:DQ
NYSE:DQSemiconductor

Should Daqo’s (DQ) Lower 2025 Output And 2026 Guidance Reset Its Profitability And Scale Narrative?

Daqo New Energy Corp. recently reported past fourth-quarter 2025 results, with sales rising to US$221.71 million while recording a net loss of US$7.28 million, alongside weaker full-year revenue and losses. The company also disclosed a sharp year-on-year drop in 2025 polysilicon production to 123,652 MT and set 2026 output guidance of 140,000–170,000 MT, giving investors clearer visibility on how it plans to use its capacity. We will now examine how Daqo’s reduced 2025 polysilicon output and...
NasdaqCM:PROP
NasdaqCM:PROPOil and Gas

A Look At Prairie Operating (PROP) Valuation As Leadership Shake-Up Raises Questions On Future Direction

Prairie Operating (PROP) is back in focus after a sweeping leadership reshuffle, including the resignation of CEO Edward Kovalik, the retirement of President Gary C. Hanna, and new interim appointments at the top. See our latest analysis for Prairie Operating. Those leadership changes arrive after a mixed stretch for investors, with the latest share price at $1.90, a 7 day share price return of 15.15% and a 1 year total shareholder return decline of 70.99%. This signals fading longer term...
NYSE:RERE
NYSE:RERESpecialty Retail

Assessing ATRenew (NYSE:RERE) Valuation After New Board Appointments And Upcoming Q4 2025 Earnings Call

ATRenew (RERE) has drawn fresh attention after appointing JD.com investment director Yue Teng to its board and compensation committee, alongside Rui Zhu joining the nominating and corporate governance committee, ahead of its Q4 2025 earnings release. See our latest analysis for ATRenew. The board appointments and upcoming Q4 2025 earnings call sit alongside a sharp pick up in the share price, with a 1 day share price return of 11.69% and 7 day share price return of 15.86%. The 1 year total...
NYSE:RNG
NYSE:RNGSoftware

RingCentral AIR Pro Launch Puts AI Healthcare Agents In Investor Focus

RingCentral has launched RingCentral AIR Pro, an AI powered, voice first omnichannel agent platform. The platform offers a no code environment for building and deploying digital agents across channels. AIR Pro debuts with healthcare focused capabilities, including support for integrations with major electronic health record systems. RingCentral, traded as NYSE:RNG, is introducing AIR Pro at a time when its shares trade around $40.69. The stock has seen strong recent momentum, with returns...
NYSE:YALA
NYSE:YALAInteractive Media and Services

Yalla Group (YALA) Margins Above 40% Challenge Market Skepticism On Slower Growth Guidance

Yalla Group (YALA) has rounded out FY 2025 with fourth quarter revenue of about US$83.9 million and basic EPS of US$0.23, against a trailing twelve month EPS of US$0.96 that sits alongside earnings growth of 10.4% year on year. Over the past six quarters in the dataset, revenue has moved within a tight band between roughly US$83.9 million and US$90.8 million per quarter, while quarterly EPS has ranged from about US$0.20 to US$0.27, feeding into a trailing net profit margin of 43.8% that is...
NYSE:KRO
NYSE:KROChemicals

Kronos Worldwide (KRO) Q4 Loss Deepens To US$0.72 EPS And Tests Profit-Recovery Hopes

Kronos Worldwide (KRO) closed out FY 2025 with Q4 revenue of US$418.3 million and a basic EPS loss of US$0.72, capping off a trailing twelve month period where revenue totaled US$1.9 billion and basic EPS came in at a loss of US$0.96. Over recent quarters, the company has seen revenue move from US$423.1 million and basic EPS of a US$0.11 loss in Q4 2024 to US$489.8 million with EPS of US$0.16 in Q1 2025, before stepping down to US$456.9 million and a US$0.32 loss in Q3 2025 and ending at...
NasdaqGS:AMBA
NasdaqGS:AMBASemiconductor

Is There Now An Opportunity In Ambarella (AMBA) After Recent Share Price Weakness

If you are wondering whether Ambarella's current share price offers value or just more volatility, you are not alone and this article is here to help you weigh that up clearly. The stock last closed at US$54.00, with returns of a 4.5% decline over 7 days, a 17.2% decline over 30 days, a 28.2% decline year to date, a 3.8% gain over 1 year, a 29.5% decline over 3 years and a 51.2% decline over 5 years. Taken together, this gives you a mixed picture of short term pressure and longer term swings...
NasdaqGS:MGNX
NasdaqGS:MGNXBiotechs

MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative

MacroGenics (MGNX) has wrapped up FY 2025 with fourth quarter revenue of US$41.2 million and a basic EPS loss of US$0.22, as the market weighs these results against a share price of US$3.43. The company has seen revenue move from US$110.7 million in Q3 2024 to US$72.8 million in Q3 2025, while basic EPS shifted from a profit of US$0.90 to a profit of US$0.27 over the same period, creating a mixed picture on topline scale and per share results. Overall, margins remain under pressure, which...
NYSE:NEU
NYSE:NEUChemicals

A Look At NewMarket (NEU) Valuation After Recent Share Price Weakness

NewMarket stock at a glance NewMarket (NEU) has caught investor attention after recent trading left the shares with a month return of about a 14% decline and a past 3 months return near a 19% decline. See our latest analysis for NewMarket. Despite the recent 30 day share price return of about a 14% decline and a 90 day share price return near a 19% decline, NewMarket’s 1 year total shareholder return of about 15% and multi year total shareholder returns above 70% indicate longer term holders...
NasdaqGS:TTAN
NasdaqGS:TTANSoftware

Is It Time To Reassess ServiceTitan (TTAN) After Its Recent Share Price Pullback?

This article is designed to help you think about whether ServiceTitan is starting to look like good value or remains priced for high expectations. The stock recently closed at US$77.90, with returns of 2.8% over 7 days and 22.2% over 30 days, while year to date it shows a 23.3% decline and a 1-year return of an 8.4% decline. Recent news coverage has focused on ServiceTitan as a key software provider for trades and home services companies, highlighting its role in helping contractors manage...
NasdaqCM:IRD
NasdaqCM:IRDBiotechs

Opus Genetics (IRD) Trailing US$49.6m Loss Reinforces Bearish Profitability Narrative

Opus Genetics (IRD) has reported FY 2025 results with Q4 revenue of US$3.9 million, a basic EPS loss of US$0.21, and a net income loss of US$16.5 million. The trailing twelve month figures show revenue of US$14.2 million, a basic EPS loss of US$0.80, and a net income loss of US$49.6 million. Over the recent quarters in FY 2025, the company has reported revenue between US$2.9 million and US$4.4 million, while quarterly basic EPS losses have ranged from US$0.12 to US$0.25 per share. These...
NasdaqGS:GLRE
NasdaqGS:GLREInsurance

Greenlight Capital Re (GLRE) Q4 Combined Ratio Of 92.1% Tests Underwriting Quality Narratives

Greenlight Capital Re (GLRE) has wrapped up FY 2025 with fourth quarter revenue of US$210.5 million and basic EPS of US$1.47, capping a trailing 12 month period that delivered EPS of US$2.21 on revenue of US$721.3 million. Over the last few quarters, revenue has ranged from US$148.1 million to US$210.5 million, while quarterly EPS has swung between a loss of US$0.13 and a profit of US$1.47. This gives investors a fuller picture of how the year built to the latest result. With a trailing net...
NYSE:DLX
NYSE:DLXCommercial Services

Deluxe Board Change Raises Questions For Payments And Cloud Transition

Deluxe (NYSE:DLX) has announced that Director Cheryl E. Mayberry McKissack will step down from its board and will not stand for re election. The board change is scheduled to take effect at the company’s upcoming annual meeting. For shareholders watching Deluxe, a company involved in payments, cloud, and data driven marketing services, board composition is one of the levers that can influence long term priorities. As the broader payments and business services space continues to evolve,...
NasdaqGS:BSY
NasdaqGS:BSYSoftware

Will Strong 2025 Results and 2026 Guidance Shape Bentley Systems' (BSY) AI and ARR Narrative?

Bentley Systems, Incorporated recently reported fourth-quarter and full-year 2025 results showing year-over-year increases in revenue and net income, affirmed full-year 2026 revenue guidance in the range of US$1.69 billion to US$1.72 billion, and declared a US$0.07 per share first-quarter 2026 dividend payable on March 19, 2026. This combination of higher earnings, forward revenue guidance, and a continued cash dividend appears to have reinforced analyst optimism about Bentley’s earnings...
NYSE:GEF
NYSE:GEFPackaging

Can Greif (GEF) Still Shape Its Margin Story Through Fresh Price Hikes?

In early March 2026, Greif Inc. announced price increases of US$60 to US$70 per short ton on all uncoated recycled paperboard grades effective from April 6, alongside at least a 7.5% rise on tube, core, and protective packaging products from April 13, citing higher labor, utilities, manufacturing, and transport costs. This pricing move underscores Greif’s ability to pass through rising input costs across its recycled paperboard and converted packaging portfolio, which could influence...
NasdaqGS:KVHI
NasdaqGS:KVHICommunications

KVH Industries (KVHI) Q4 Profitability Return Challenges Persistent Loss Narrative

KVH Industries (KVHI) closed out FY 2025 with Q4 revenue of US$30.5 million and basic EPS of roughly US$0.02, alongside net income of about US$0.3 million. Over the past year, the company has seen quarterly revenue range from US$25.4 million to US$30.5 million, while basic EPS has swung between a loss of around US$0.36 in Q3 2025 and a profit of about US$0.05 in Q2 2025. This gives investors a clear view of how volatile margins have been. With trailing 12 month figures still pointing to an...
NYSE:TAP
NYSE:TAPBeverage

Is Molson Coors (TAP) Offering Quiet Value After Its Recent Share Price Slide

If you are wondering whether Molson Coors Beverage shares are pricing in too much pessimism or offering quiet value, this is a good moment to take a closer look. The stock recently closed at US$45.87, with returns of a 4.6% decline over 7 days, an 11.4% decline over 30 days, a 3.2% decline year to date, a 21.0% decline over 1 year, and a 2.5% decline over 3 years, compared with a 10.0% gain over 5 years, which may have changed how investors see its risk and potential. Recent coverage of...
NYSE:FCPT
NYSE:FCPTSpecialized REITs

Four Corners Expands Auto Service Portfolio With Indiana And Texas Deals

Four Corners Property Trust (NYSE:FCPT) has acquired automotive service properties in Texas and Indiana. Each property is operated under a long term triple net lease with a national automotive service tenant. The transactions extend FCPT’s reach beyond casual dining into essential, car focused retail locations. For you as an investor, these new deals highlight how Four Corners Property Trust, known for its net lease portfolio centered on restaurants, is adding more automotive service assets...
NasdaqGM:CHRS
NasdaqGM:CHRSBiotechs

Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses

Coherus Oncology (CHRS) just posted its FY 2025 numbers with Q4 revenue of US$12.7 million and a basic EPS loss of US$0.39, while trailing 12 month figures show revenue of US$42.2 million and a basic EPS loss of US$1.56. Over recent quarters, the company has seen revenue move from US$7.6 million in Q1 2025 to US$12.7 million in Q4 2025, with quarterly basic EPS losses in a tight band around US$0.38 to US$0.41. This keeps the focus squarely on how efficiently each extra dollar of sales is...
NasdaqGS:INVA
NasdaqGS:INVAPharmaceuticals

How Investors May Respond To Innoviva (INVA) Surging EPS From Continuing Operations

In February 2026, Innoviva, Inc. reported fourth-quarter 2025 revenue of US$114.61 million and net income of US$164.15 million, alongside full-year revenue of US$411.33 million and net income of US$271.17 million, all higher than the prior year. An interesting feature of this release is the sharp increase in basic earnings per share from continuing operations, with quarterly EPS rising to US$2.19 and full-year EPS reaching US$4.02 compared with the previous year. We’ll now explore how...
NYSE:RCUS
NYSE:RCUSBiotechs

Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion

Arcus Biosciences recently reported full-year 2025 results, with revenue of US$247 million versus US$258 million in 2024 and a net loss of US$353 million, while also granting new employee equity awards under its 2020 Inducement Plan. More importantly for the story, Arcus outlined encouraging new clinical data and expansion plans for its HIF-2α inhibitor casdatifan in kidney cancer, alongside moves into inflammatory and autoimmune diseases that could reshape how investors view its pipeline...